Triggers falling in place for Dr Reddy's

As facilities get US FDA nod, pace of product launches will improve

A go-ahead from the US Food and Drug Administration (FDA) for its Miryalaguda plant in Telangana could trigger the start of a new approval cycle for Dr Reddy’s Laboratories. The plant, one of three under the FDA scanner, was inspected by the latter in February, with three observations. It was recently issued an Establishment Inspection Report (EIR), which marks the end of successful inspection. And, could indicate the company is close to solving issues related to the earlier warning letter.

The event also raises hope that the company’s larger Srikakulam facility, in Andhra that had also not received any material observations